Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.

about

Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.

Item

http://www.wikidata.org/entity/Q41162110

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Responses to crizotinib and ch ...... and review of the literature.

@en

type

Item

label

Responses to crizotinib and ch ...... and review of the literature.

@en

prefLabel

Responses to crizotinib and ch ...... and review of the literature.

@en

P1476

Responses to crizotinib and ch ...... and review of the literature.

@en

P2093

Bicheng Chen

http://www.w3.org/2001/XMLSchema#string

Chengshui Chen

http://www.w3.org/2001/XMLSchema#string

Guoping Cai

http://www.w3.org/2001/XMLSchema#string

Jinsheng Ouyang

http://www.w3.org/2001/XMLSchema#string

Junru Ye

http://www.w3.org/2001/XMLSchema#string

Quan Lin

http://www.w3.org/2001/XMLSchema#string

Shanshan Su

http://www.w3.org/2001/XMLSchema#string

Xiuling Wu

http://www.w3.org/2001/XMLSchema#string

Ying Zhou

http://www.w3.org/2001/XMLSchema#string

Yuping Li

http://www.w3.org/2001/XMLSchema#string

P2860

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizo

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.

Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma

P304

173-182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2017.1306

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28781781

http://www.w3.org/2001/XMLSchema#string

P921

crizotinib

P932

5532680

http://www.w3.org/2001/XMLSchema#string